新辅助化疗对乳腺癌的疗效及影响因素分析  

Efficacy and impact factors analysis of Neoadjuvant chemotherapy for breast cancer

作　　者：王妍[1] 贾羽峰[1] 井明晰[1] 段博实[1] 鄂颖[1] 孙涛[1] 

机构地区：[1]辽宁省肿瘤医院乳腺内科,辽宁沈阳110042

出　　处：《中国医药导报》2013年第11期45-47,共3页China Medical Herald

基　　金：辽宁省第一批次科学技术计划项目(编号2011225019)

摘　　要：目的探讨及分析新辅助化疗对乳腺癌的疗效及影响因素。方法选择2008年12月～2011年l2月在辽宁省肿瘤医院就诊的80例局部晚期乳腺癌患者作为研究对象,比较不同肿瘤大小、不同肿瘤分级及肿瘤分期、不同化疗方案以及不同淋巴结个数的有效率(RR)。结果 80例乳腺癌患者根据国际抗癌联盟(UICC)实体瘤疗效标准评价,结果显示,完全缓解(CR)24例,部分缓解(PR)40例,病情稳定(SD)16例,疾病进展(PD)0例,RR为80.0%(64/80)。不同肿瘤大小、不同肿瘤分期、以及不同淋巴结个数的RR比较,差异有统计学意义(P<0.05)。结论新辅助化疗对乳腺癌具有较好的疗效,但其疗效受肿瘤大小、不同肿瘤分期、以及不同淋巴结个数相关因素的影响。Objective To investigate the efficacy and impact factors of neoadjuvant chemotherapy on the breast cancer. Methods Selected 80 patients with locally advanced breast cancer patients as research subjects from December 2008 to December 2011 in our hospital, the efficiency （RR） of different tumor size, different tumor grade and tumor stage, chemotherapy, and different lymph node were compared. Results According to the UICC solid tumors criteria evaluation, in the 80 breast cancer patients,the CR 24, PR 40, SD 16, PD, RR was 80.0% （64/80）. The RR of different tumor size, tumor staging, and different number of lymph were compared, the difference was statistically significant （P 〈 0.05）. Conclusion The new adjuvant chemotherapy for breast cancer have a good effect, but its efficacy is impact by tumor size, different tumor stages, as well as the different lymph node number of related factors.

关 键 词：乳腺癌 新辅助化疗 疗效 预后 影响因素 

分 类 号：R737.9[医药卫生—肿瘤]